Susquehanna Fundamental Investments LLC Invests $10.90 Million in Revvity, Inc. (NYSE:RVTY)

Susquehanna Fundamental Investments LLC bought a new stake in Revvity, Inc. (NYSE:RVTY - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 97,632 shares of the company's stock, valued at approximately $10,897,000. Susquehanna Fundamental Investments LLC owned 0.08% of Revvity at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RVTY. T. Rowe Price Investment Management Inc. grew its position in Revvity by 16.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 20,761,308 shares of the company's stock worth $2,317,170,000 after purchasing an additional 2,969,326 shares during the period. Vanguard Group Inc. lifted its position in shares of Revvity by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 14,290,211 shares of the company's stock valued at $1,594,930,000 after buying an additional 156,679 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Revvity by 17.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,631,597 shares of the company's stock valued at $851,764,000 after buying an additional 1,151,821 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Revvity by 2.1% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,382,338 shares of the company's stock valued at $384,234,000 after acquiring an additional 69,034 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Revvity by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 2,901,459 shares of the company's stock worth $322,958,000 after acquiring an additional 37,666 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity Stock Up 1.5 %

RVTY stock traded up $1.38 during trading on Friday, hitting $94.28. 408,398 shares of the company's stock were exchanged, compared to its average volume of 927,637. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. The business has a 50-day moving average price of $103.23 and a two-hundred day moving average price of $112.33. The stock has a market capitalization of $11.33 billion, a price-to-earnings ratio of 42.66, a PEG ratio of 3.82 and a beta of 1.07. Revvity, Inc. has a 52-week low of $88.53 and a 52-week high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings results on Monday, April 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.96 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The firm had revenue of $664.76 million for the quarter, compared to the consensus estimate of $662.30 million. During the same quarter last year, the business posted $0.98 EPS. The firm's quarterly revenue was up 2.3% compared to the same quarter last year. As a group, equities research analysts expect that Revvity, Inc. will post 4.94 EPS for the current year.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, July 18th. This represents a $0.28 annualized dividend and a dividend yield of 0.30%. Revvity's dividend payout ratio (DPR) is 11.91%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on RVTY shares. The Goldman Sachs Group decreased their price target on shares of Revvity from $140.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday. Wells Fargo & Company cut their price objective on shares of Revvity from $130.00 to $102.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Barclays reduced their target price on Revvity from $140.00 to $110.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. UBS Group raised shares of Revvity from a "neutral" rating to a "buy" rating and decreased their target price for the company from $145.00 to $115.00 in a research report on Thursday. Finally, Robert W. Baird dropped their target price on shares of Revvity from $127.00 to $125.00 and set an "outperform" rating for the company in a report on Tuesday. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $125.64.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.